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INTRODUCTION 
Vitamin D: the sunshine vitamin. 
Vitamin D is a unique nutrient in that it is not only obtained from food, but it is also 
produced in appreciable quantities in the skin.  Endogenous production of vitamin D begins with 
UVB irradiation, which forces the B-ring of steroidal pro-vitamin D to break at the ninth carbon.  
Pre-vitamin D compounds are then isomerized by heat to form vitamin D 
1
.  The dietary 
guidelines for vitamin D consumption have recently been revised by the Institute of Medicine 
and raised to 600-800 International Units (IU)/day, depending on age 
2
.   
Whether ingested through the diet, or made in the skin, vitamin D is readily hydroxylated 
by 25 hydroxylase to 25-hydroxyvitamin D (25OH D) in the liver and deposited into circulation 
attached to the vitamin D binding protein.  Further hydroxylation of 25OH D at the first carbon 
by CYP27B1 results in the formation of 1,25-dihydroxyvitamin D (1,25(OH)2 D).  This 
metabolite is considered the active form of vitamin D because it directly binds to the nuclear 
vitamin D receptor, which regulates numerous transcription factors. The formation of 1,25-
dihydroxyvitamin D is tightly regulated, and as such, this metabolite subsists at low levels 
approximated at 1000 times less than that of 25OH D 
3
.  25OH D and 1,25-dihydroxyvitamin D 
are both rendered inactive by CYP24, which hydroxylates these metabolites at the twenty-fourth 
carbon.   
Vitamin D and Non-Melanoma Skin Cancer 
 Non melanoma skin cancer (NMSC) is the most prevalent type of cancer in the United 
States with approximately 2.2 million people diagnosed each year 
4
.  Although this disease is not 
particularly deadly, the cost incurred through treatment of the disease is a severe burden for those 
affected 
5
.   The most easily modifiable risk factor for NMSC is unprotected UV exposure, yet 
some researchers suggest that individuals receive approximately 5-15 minutes of unprotected sun 
exposure three times a week for sufficient vitamin D production 
6
.  Other researchers suggest that 
moderate unprotected sun exposure allows for sufficient production of vitamin D without 
significantly increasing a person’s risk for skin cancer 6.  Still, it is reasonable to expect that 
individuals following such advice will remain in the sun for longer than necessary, increasing the 
risk of developing UV-induced skin cancer 
7
.  
The role of vitamin D in NMSC is also not well known.  Most of the studies investigating 
the relationship between vitamin D and NMSC focus on basal cell carcinoma (BCC), one of the 
subtypes of NMSC.  Two prospective studies investigating the relationship of several dietary 
nutrients and BCC concluded that dietary vitamin D had no protective effect against BCC 
8,9
.  It 
should be noted that these studies did not measure serum 25OH D levels, and thus lack a proper 
biomarker to verify vitamin D intake and status.  Asgari and colleagues 
10
 reported an increased 
risk for BCC with higher prediagnostic serum 25OHD levels in a nested case control study.  
Epidemiological studies investigating the relationship between vitamin D status and general 
NMSC, including BCC and squamous cell carcinoma (SCC), have found conflicting results.  
Tang and colleagues 
11
 found that higher baseline 25OH D serum levels coincided with a 
decreased risk for self-reported NMSC, while Eide et al 
12
 reported an increased risk of 
histologically confirmed NMSC with higher baseline 25OH D levels.   Epidemiological studies 
on this subject are challenging in that it is difficult to control for sun exposure as a confounding 
factor since it contributes to both vitamin D status and NMSC risk. 
Cell and animal studies, while not conclusive, have provided some intriguing evidence on 
the role of vitamin D in NMSC.  Much of the interest in this interaction stems from the fact that 
keratinocytes, melanocytes, and even cancer cells contain cellular machinery related to vitamin 
D, including the vitamin D receptor and metabolizing enzymes 
13,14
.  Traditionally it has been 
assumed that 1,25(OH)2 D has pro-differentiating and anti-proliferating activities in healthy 
keratinocytes, while SCC cells lose sensitivity to the pro-differentiating signaling of 1,25(OH)2 
D.  However, it has been suggested that the concentration of 1,25(OH)2 D may also influence cell 
growth, with lower concentrations exhibiting a pro-proliferative effect in healthy skin cells and 
high doses having the opposite effect 
10
.  There is even conflicting evidence on whether or not 
topical application of 1,25(OH)2 D is anti- or pro-proliferative 
15,16
.  There is a decent amount of 
evidence on the ability of 1,25(OH)2 D to protect skin cells against many types of UV-induced 
DNA damage 
17
.  The modulation of the DNA damage response by 1,25(OH)2D has been 
recently reviewed by Bikle 
18
.  In all, the evidence for a role of vitamin D in NMSC is still rather 
inconclusive. 
Most investigators focus on the utility of pure 1,25(OH)2 D  against NMSC rather than 
dietary vitamin D.  This is not surprising, as epidemiological evidence has suggested that the 
effects of dietary vitamin D are insignificant, especially when compared to the experimentally 
verified effects of 1,25(OH)2 D 
14
.  However, no animal or human trial has yet investigated the 
effects of dietary vitamin D on the development of NMSC.  
 
Vitamin D Analysis 
The most commonly measured metabolites of vitamin D are the 25-hydroxylated forms of 
vitamins D2 and D3.  The additive concentration of these two metabolites yields the clinically 
relevant measurement of vitamin D status.  Although it is not the active form of vitamin D, total 
serum 25OH D level is considered the best measurement of status for several reasons. Vitamin D 
produced endogenously or absorbed from the diet is rapidly converted to 25OH D, and the half-
life of this metabolite is approximately 15 days, compared to 15 hours for the active 1,25(OH)2 D 
metabolite 
19
.  Additionally, 25OH D circulates at much higher concentrations than 1,25(OH)2  D 
and may be less influenced by other factors 
3
. 
Determination of vitamin D status has been a notable challenge in clinical laboratories, as 
there is great discrepancy not only between methods used for measurement, but also between 
laboratories performing the assays.  The common methodology used to measure vitamin D 
status, as well as issues with the current assays, have recently been reviewed by Su and 
colleagues 
3
.  The four most common methods used for 25OH D quantification include vitamin 
D binding protein-based competitive protein-binding assays, immunoassays, and high 
performance liquid chromatography (HPLC) assays with UV or mass spectral detection. 
Competitive binding protein assays and immunoassays are popular mainly due to their ease and 
affordability.  However, these techniques are susceptible to overestimation of 25OH D3 due to 
interfering metabolites of vitamin D3, especially C3-epi 25OH D3 (C3epi), and underestimation 
of 25OH D2 due to lower binding affinity 
3,20,21
.  Techniques involving HPLC may separate some 
interfering compounds from 25OH D.  Thus, among all these methods, it is generally agreed that 
HPLC coupled with tandem mass spectrometry is the preferred method for vitamin D analysis 
22
.   
 In order to further increase the sensitivity of HPLC-MS/MS methods, several groups 
have begun employing chemical derivatization with Cookson-type reagents.  These reagents are 
4-substituted 1,2,4-triazoline-3,5-dienes that react with conjugated diene systems in a Diels-
Alder fashion 
23
.  Derivatizing vitamin D metabolites with these agents increase ionization 
efficiency and provide more specific and predictable mass transitions 
23,24
.  A number of 
Cookson-type reagents have been suggested for use in vitamin D analysis 
20
, but the most 
prevalent, and possibly the most commercially available, is 4-phenyl-3H-1,2,4-triazole-3,5(4H)-
dione (PTAD).  PTAD has been used successfully to profile vitamin D metabolites in serum 
25–
27
, and soft tissues 
28
, but other mediums, such as murine skin, have been left unexplored.  
Additionally, no current vitamin D analysis method utilizing PTAD derivatization has reported 
the separation of 25OH D3 and C3epi. 
 The objectives of this study were to develop methodology appropriate for the 
measurement of vitamin D metabolites in murine skin, and apply the developed method to 
quantify 25OH D3 levels in the skin of mice from a study investigating the effects of dietary 
vitamin D3 on NMSC.  
 
MATERIALS AND METHODS 
Samples 
 To study the effects of dietary vitamin D on the occurrence of NMSC, the Skh-1 mouse 
model was used.  This model is well-accepted model for the study of NMSC, and more 
specifically SCC 
29
.  Male (n=75) and female (n=75) mice were fed 25, 150, or 1000 IU vitamin 
D3 in their chow (n=25/sex/diet).  After four weeks, these groups were further divided into 
treatment groups with n=15/sex/diet receiving one minimal erythemial dose of UVB irradiation 
three times per week and n=10/sex/diet receiving no UV treatment for 25 weeks.  Dorsal skin 
from n=3 mice from each sex/diet/treatment group (total n=36) was analyzed for vitamin D 
metabolites.  
 
Sample Preparation 
Skin samples (0.30 g) were frozen with liquid nitrogen, crushed to a fine powder, and 
transferred into pre-weighed glass vials.  Samples were then spiked with 20 µL of a d325OH D3 
solution (100 nmol/L) and extracted with the solvent system used by Stahl and others 
30
 with 
slight modifications 
31
.  Briefly, 1 mL of ethanol containing 0.1% butylated hydroxytoluene, 1 
mL of water, and 5 mL of 5:1 hexane/dichloromethane were added to the skin samples, and the 
mixture was probe soicated for 30 s.  The homogenized solutions were centrifuged at 2000 x g 
for 5 min to hasten phase separation, and the upper organic layer was decanted into clean glass 
vials.  The extraction was repeated another two times, with the addition of 5 mL 5:1 
hexane/dicholormethane, and the pooled organic layers were dried under a stream of nitrogen. 
Standards of 25OH D3 ranging in concentration from 7.80 to 250 nmol/L were spiked with 20 µL 
of the internal standard solution, dried, and processed alongside extracted skin samples as 
described below.  
Dried extracts were derivatized using 4-Phenyl-1,2,4-triazole-3,5-dione (PTAD) 
according to Lipkie et al 
28
.  100 µL of a 2 mg/mL PTAD solution were added to the extracts, 
which were then mixed on a vortex for 10 min.  An additional 100 µL of PTAD was added to the 
solution and mixing was repeated for another 10 min.  The reaction was quenched by adding 20 
µL of water and mixing for 5 additional minutes.  The reaction mixture was dried under nitrogen, 
reconstituted with 100 µL of acetonitrile, and centrifuged at 15,000 x g for 2 min prior to 
analysis.  
 
HPLC-MS/MS Analysis 
Vitamin D metabolites were separated by HPLC using a Luna C18 reversed phase 
column (4.6x250 mm, 5 µm; Phenomenex, Torrance, CA) maintained at 40 °C.  The binary 
mobile phase consisted of water (A) and acetonitrile (B), both containing 0.1% formic acid.  
Optimal separation of vitamin D metabolites was achieved using a step gradient of 29% A for 
3.5 min and an immediate switch to 20% A for 3 min, followed by a column wash with 100% B 
for two minutes and reconditioning at initial conditions for 3.5 min.  The injection volume was 
10 µL and the injection needle was washed with acetonitrile between runs.  Eluent from the 
HPLC was directed to a QTRAP 5500 mass spectrometer (AB Sciex; Framingham, MA) 
equipped with atmospheric pressure chemical ionization (APCI) operated in positive ion mode.  
MS parameters were as follows: source temperature, 450 °C; curtain gas, 30 psi; ion source gas 
1, 60 psi; ion source gas 2, 0 psi; declustering potential, 185 V; entrance potential, 10 V; 
collision cell exit potential, 11 V.  Specific MS parameters are elaborated in table 1. 
25OH D3 and C3-epi-25OH D3 were quantified using isotope dilution methodology with 
Analyst 1.5.1 (ABSciex; Foster City, CA).  Briefly, standards with varying concentrations of 
25OH D3 were spiked with a constant concentration of d325OH D3 and processed as described 
above.  The areas under the peaks representing derivatized 25OH D3 and its labeled counterpart 
were calculated, and a standard curve was constructed using the ratio of labeled to unlabeled 
standard.  25OH D3 and C3-epi-25OH D3 in the skin extracts were quantified using this standard 
curve.   
 
Table 1. Relevant parameters used for the analysis of vitamin D metabolites 
Analyte 
Retention 
Time (min) 
Mass Transition 
Collison 
Energy (V) 
Dwell 
Time 
(ms) 
PTAD-25OH D3 5.9 558.3 > 298.3 25 280 
PTAD-C3-epi-25OH 
D3 
6.2 558.3 > 298.3 25 280 
PTAD-d325OH D3 6.3 561.3 > 301.3 25 280 
 
 
    
Statistical Analysis 
 Statistical significance (p<0.05) was calculated using multivariate analysis and Tukey’s 
post-hoc test in SPSS (IBM, Armonk, NY). 
 
RESULTS AND DISCUSSION 
 The first objective of this work was to develop methodology appropriate for the analysis 
of vitamin D metabolites in skin.  The metabolites successfully profiled in skin were 25OH D3 as 
well as the C3-epimer of this compound (C3epi).  To our knowledge, this is the first time that 
this analysis has been performed in murine skin, and we are the first to chromatographically 
separate PTAD-derived 25OH D3 and C3-epi for quantification.   The separation of these PTAD-
derived metabolites was challenging due to the fact that derivatization with PTAD results in the 
formation of (R) and (S) enantiomers of each derived compound 
32
.  The example chromatogram 
of PTAD-25OH D3 and PTAD-C3epi standards (figure 1) details the elution pattern of these 
compounds on the Luna C18 column.  The two enantiomers of PTAD-C3epi co-elute between 
the two enantiomers of PTAD-25OH D3. The method was found to be sufficiently sensitive for 
the detection and quantification of these metabolites in murine skin. 
 
 
Figure 1. Example chromatogram of PTAD-derivatives of 25OH D3 and C3epi standards 
 
 The developed method was applied to measure vitamin D metabolites in a study of 
effects of dietary vitamin D on NMSC in mice.  In this study, mice were fed increasing amounts 
of vitamin D while being exposed or remaining unexposed to UVB irradiation.  Since vitamin D 
is produced via UVB irradiation of the skin, vitamin D status (25OH D3) in the skin was 
expected to be greater for those mice receiving the UVB treatment than those not receiving the 
treatment.  Surprisingly, no significant differences from this treatment were noticed in these 
mice.  However, a dose-dependent response was detected regardless of UV exposure.  As shown 
in figure 2, the 25OH D3 level in the skin reflected increases in dietary vitamin D3 with statistical 
significance between each dose.  Interestingly, C3epi levels increased significantly only at the 
highest dose, suggesting that this metabolite may become more important in a high-vitamin D 
state.  
 
Figure 2. Vitamin D metabolite levels in skin of mice fed increasing doses of vitamin D3.  
Significant differences are denoted by * and lower case letters for 25OH D3 and C3epi, 
respectively. Error bars represent standard error. (n=12 mice/dose).    
 
 Apart from differences between the skins of mice fed increasing amounts of vitamin D3, 
few other significant differences appeared in this sample set. However, when examining the 
dose-response data with regard to sex, there was a significant difference in the C3epi levels of 
male and female mice fed 1000 IU vitamin D3. No other differences were noticed between male 
and female mice in this work.  The metabolite levels of male and female mice at each dose level 
are shown in figure 3. Though the difference between males and females was slight, it is still 
interesting, as sex is believed to influence NMSC.  Females tend to develop less NMSC than 
males 
7
.   Remarkably, the levels of 25OH D3 were similar for both males and females at all three 
doses of vitamin D3.  
 The data collected in this work will be used to help explain the results seen in the 
histology and other cancer outcomes of this mouse study.  Future work will include serum 
measurements of 25OH D3 and C3epi from the same mice. The method that was developed for 
this analysis is expected to have a strong impact on future work with vitamin D.  As researchers 
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become more interested in low-abundant metabolites of vitamin D in the tumor micro-
environment, sensitive methods that are able to separate derived 25OH D3 and C3epi will be vital 
for accurate measurements of these compounds.  
 
 
Figure 3. Vitamin D metabolite levels in skin of male and female mice fed increasing doses of 
vitamin D3.  Significant differences are denoted by * and lower case letters for 25OH D3 and 
C3epi, respectively. Error bars represent standard error. (n=6 mice/dose/sex).  
 
  Conclusions 
 We have shown, for the first time, a dose-dependent increase of 25OH D3 levels in skin 
from mice fed increasing amounts of vitamin D3.  Additionally, differences in C3epi levels of 
male and female mice fed 1000 IU vitamin D3 were found.  These measurements were possible 
due to a newly developed method which chromatographically separates PTAD-derivatized 25OH 
D3 and C3epi.  The results of this study will no doubt inform future studies of the effects of 
dietary vitamin D on NMSC and facilitate more accurate measurements of derivatized 25OH D3 
levels.  
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